Emergent BioSolutions stock jumps 19.6% on suspected plague death in Siberia

Emergent BioSolutions' stock surged approximately 19.6% to $7.57 in afternoon trading following reports of a suspected pneumonic plague death at a Russian institute in Siberia, prompting investors to focus on biodefense stocks. The U.S. State Department, including Secretary Marco Rubio, is monitoring the incident at the Irkutsk Anti-Plague Institute and has requested accurate information from Russia. The company also reported strong quarterly results, with adjusted EPS of $0.60 and revenue of $234.3 million, significantly beating expectations. Analysts maintain a consensus "Hold" rating with a $12-month average price target of $10.00. The stock had fallen about 49% year-to-date before this surge, and the company has reduced total debt to $515 million following refinancing and bond buybacks.